GLP-1 Drugs Linked to Improved Survival in Real-World Cancer Analysis

Patients with cancer who received glucagon-like peptide-1 receptor agonists were associated with a 34% lower risk of death than nonusers in a large real-world analysis presented at the 2026 American Society of Clinical Oncology Annual Meeting, prompting calls for prospective trials.

The analysis examined patients treated in community oncology practices across multiple cancer types. Investigators used several statistical approaches intended to reduce bias, but the observational study could not establish that GLP-1 therapy caused the survival difference.

Key Points

• A community oncology analysis associated GLP-1 receptor agonist use with a 34% lower risk of death among patients with cancer.
• Researchers affiliated with Ontada presented the findings at the 2026 American Society of Clinical Oncology Annual Meeting.
• The evidence could broaden GLP-1 research beyond diabetes and obesity, although safety concerns and the absence of randomized trial data remain barriers.

GLP-1 receptor agonists mimic a hormone involved in blood-sugar regulation, appetite and digestion. Medicines in this class, including semaglutide-based treatments, are widely prescribed for type 2 diabetes and obesity—conditions that frequently affect cancer patients and survivors.

Jessica Paulus, ScD, of healthcare data and research organization Ontada, said the results were consistent across several analytical methods. However, she emphasized that the findings show an association and require confirmation through prospective studies.

Interest in a possible relationship between GLP-1 medicines and cancer has expanded as use of the drugs has increased. A late-2025 KFF poll cited by MDLinx estimated that 12% of US adults were taking a GLP-1 medicine, twice the proportion recorded approximately 18 months earlier.

Use is also becoming more common among people with a history of cancer. An analysis of 2024 National Health Interview Survey data presented at the ASCO meeting estimated that injectable GLP-1 medicines were used by 21.2% of cancer survivors with diabetes and 27.6% of survivors with obesity.

According to Medi-Tech Insights, the global GLP-1 analogues market is expected to grow at a compound annual growth rate of 14% during the forecast period. Growth is being supported by the rising prevalence of type 2 diabetes and obesity, greater adoption for chronic weight management among people without diabetes, expanding pharmaceutical research pipelines and increasing demand in emerging markets with a high metabolic disease burden. Strict regulatory requirements and limited reimbursement policies, however, remain significant restraints on the market.

Separate retrospective evidence has raised the possibility that the drug class may affect cancer development or progression. One analysis of 12,112 patients with stage I to III obesity-associated cancers reported less progression to metastatic disease among GLP-1 users than among matched patients receiving DPP-4 inhibitors.

Another target-trial emulation involving more than 229,000 adults with obesity but without diabetes associated GLP-1 therapy with a lower incidence of obesity-related cancers than lifestyle intervention alone. The research was highlighted by oncology specialists Petros Grivas of the University of Washington and Fred Hutch Cancer Center and Ashish Kamat of the University of Texas MD Anderson Cancer Center.

Grivas said the drug class “may have broader benefits,” while also stressing the continuing importance of lifestyle measures, screening, family-history assessment and genetic evaluation.

Clinicians nevertheless face a different risk-benefit calculation when prescribing these medicines to cancer survivors. Some patients have poor appetite, digestive complications or reduced muscle mass following surgery, chemotherapy or radiation, and GLP-1 treatment can cause nausea, delayed gastric emptying and further weight loss.

“A history of cancer doesn’t automatically mean someone can’t take a GLP-1 medication,” urologist Arthur Burnett II said, calling for individualized assessment.

Semaglutide prescribing information includes a contraindication for patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Additional concerns include pancreatitis, severe gastrointestinal reactions, gastroparesis and the potential effect of delayed gastric emptying on oral anticancer medicines.

The findings may encourage pharmaceutical companies, cancer centers and academic researchers to examine GLP-1 drugs in controlled oncology studies. No new cancer indication, regulatory approval, commercial partnership or oncology-specific product launch was announced alongside the analyses.

Randomized trials will be required to determine whether the reported benefits result from the medicines themselves, improved metabolic health or differences between treated and untreated patients. Researchers must also identify which cancer populations could benefit, when treatment should begin and how clinicians can protect patients’ nutrition and muscle mass.

Reference:

https://www.targetedonc.com/view/real-world-analysis-explores-glp-1-use-and-overall-survival
https://www.mdlinx.com/article/glp-1s-after-cancer-who-needs-a-different-risk-threshold/2gjgJz2YUvR4SxL4IH0aST
https://oncodaily.com/voices/petros-grivas-558094